A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma

Oncotarget
Shunsuke ShibaoMasahiro Toda

Abstract

Early-phase clinical studies of glioma vaccines have shown feasibility and encouraging preliminary clinical activity. A vaccine that targets tumor angiogenesis factors in glioma microenvironment has not been reported. Therefore, we performed a pilot study to evaluate the safety and immunogenicity of a novel vaccination targeting tumor angiogenesis with synthetic peptides for vascular endothelial growth factor (VEGF) receptor epitopes in patients with recurrent/progressive high grade gliomas. Eight patients received intranodal vaccinations weekly at a dose of 2mg/kg bodyweight 8 times. T-lymphocyte responses against VEGF receptor (VEGFR) epitopes were assessed by enzyme linked immunosorbent spot assays. This treatment was well-tolerated in patients. The first four vaccines induced positive immune responses against at least one of the targeted VEGFR epitopes in the peripheral blood mononuclear cells in 87.5% of patients. The median overall survival time in all patients was 15.9 months. Two achieved progression-free status lasting at least 6 months. Two patients with recurrent GBM demonstrated stable disease. Plasma IL-8 level was negatively correlated with overall survival. These data demonstrate the safety and immunogenicity of ...Continue Reading

References

Sep 7, 2001·Cytokine & Growth Factor Reviews·K Xie
Dec 18, 2001·International Journal of Cancer. Journal International Du Cancer·M H AndersenE Kämpgen
Jan 20, 2005·The Journal of Experimental Medicine·Catherine GermeauPierre G Coulie
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 16, 2005·Neuro-oncology·Daniel J BratErwin G Van Meir
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naoki YajimaRyuichi Tanaka
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hidenobu IshizakiHideaki Tahara
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas MackensenReinhard Andreesen
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J VredenburghHenry S Friedman
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Annick DesjardinsJames J Vredenburgh
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Aug 27, 2009·Biologics : Targets & Therapy·Michael P GustafsonAllan B Dietz
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Sep 12, 2009·Brain Pathology·Bryan D ChoiJohn H Sampson
Oct 3, 2009·Acta Neuropathologica·David CapperAndreas von Deimling
Dec 1, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alba A BrandesMartin J van den Bent
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H SampsonDarell D Bigner
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mizuhiko TerasakiKyogo Itoh
May 12, 2012·CA: a Cancer Journal for Clinicians·John M KirkwoodSoldano Ferrone
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jul 31, 2012·Japanese Journal of Clinical Oncology·Motoo NaganeMasao Matsutani
Aug 1, 2012·Cancer Immunology, Immunotherapy : CII·Surasak PhuphanichJohn S Yu
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Jul 22, 2014·Nature·Theresa SchumacherMichael Platten
Jul 2, 2015·Neuro-oncology·Kathryn M FieldMark A Rosenthal
Oct 12, 2015·Current Treatment Options in Oncology·Martha R Neagu, David A Reardon
Nov 8, 2015·The Lancet Oncology·Hideho OkadaDavid A Reardon

❮ Previous
Next ❯

Citations

Nov 1, 2018·Journal of Cellular Physiology·Masoud NajafiKeywan Mortezaee
Aug 14, 2019·Current Opinion in Oncology·Valérie DutoitPierre-Yves Dietrich
Oct 14, 2018·World Journal of Surgical Oncology·Li ZhuDihong Tang
Aug 24, 2019·Frontiers in Immunology·Michal A Rahat
Dec 19, 2019·Nature Communications·Ryota TamuraMasahiro Toda
Dec 3, 2020·Critical Reviews in Oncology/hematology·Leila JafarzadehHamid Reza Mirzaei

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

ImmunoSpot Professional
CytoVision® Analysis System
JMP
CTCAE
iRANO

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

© 2022 Meta ULC. All rights reserved